MedTrace Logo

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

NCT04221217 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of MND-2119 at a dose of 2g/day or 4g/day for 52 weeks in patients with hypertriglyceridemia.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Icosapent

Icosapent (MND-2119) capsules.

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Takuya Mori · Mochida Pharmaceutical Company, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-14
Primary Completion
2021-07-14
Completion
2021-07-14

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221217 on ClinicalTrials.gov